Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

DISEASE CHARACTERISTICS: Diagnosis of 1 of the following advanced lymphoid malignancies: Multiple myeloma, meeting both of the following criteria: Deletion of chromosome 13 Elevated pre-transplant lactic dehydrogenase Chronic lymphocytic leukemia (CLL) Failed ≥ 2 prior conventional chemotherapy regimens, including fludarabine Small lymphocytic lymphoma Follicular non-Hodgkin's lymphoma Received ≥ 3 prior conventional chemotherapy regimens Mantle cell lymphoma Received ≥ 3 prior conventional chemotherapy regimens Predicted poor outcome and relapsed disease after undergoing autologous stem cell transplantation ≥ 6 months ago Measurable disease, defined as any evidence of disease by scans or blood or urine analysis At least 8 x 10^6 autologous CD34-positive cells/kg available for transplantation Stem cell mobilization allowed Haploidentical related donor available Sex-mismatched Identical for 1 HLA haplotype AND mismatched for ≥ 1 HLA-A, -B, -C, or DRB1 locus of the unshared haplotype No HLA-identical related or unrelated donor available Not eligible for first-line autologous stem cell transplantation on protocol FHCRC-1368.00, FHCRC-1366.00, FHCRC-1461.00, or FHCRC-1595.00 No bulky disease, defined as total volume of all measurable tumor > 500 cc No CNS disease resistant to therapy PATIENT CHARACTERISTICS: Age 18 to 69 Performance status Karnofsky 70-100% Life expectancy Not specified Hematopoietic Not specified Hepatic Liver function tests or liver enzymes ≤ 2 times upper limit of normal Renal Not specified Cardiovascular Ejection fraction ≥ 45% No symptomatic cardiac disease Pulmonary DLCO ≥ 50% Other Not pregnant or nursing Fertile patients must use effective contraception HIV Negative No active infection PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics No prior allogeneic stem cell transplantation Chemotherapy See Disease Characteristics Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Other No concurrent contrast dye during and for 3 weeks after completion of interleukin-2 administration